Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis Neoleukin Therapeutics Downgraded by Zacks Investment Research on 10/12/2021. Contact us at AsktheExpert.AdisInsight@springer.com for assistance. c/o Neoleukin Therapeutics . Neoleukin Therapeutics Announced Preclinical Data ... Neoleukin Therapeutics is a smaller company with a market capitalization of US$554m, so it may still be flying under the radar of many institutional investors. --Neoleukin Therapeutics, Inc.," Neoleukin", a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three . Neoleukin Therapeutics. 0. Neoleukin Therapeutics Announces Third Quarter 2021 ... Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. Volume today is 150,531 compared to average volume of 188,006. Contact Careers Advertise Mobile Apps . Neoleukin Therapeutics. Drug: NL-201. 0 shares of the stock traded hands, compared to its average volume of 221300. Neoleukin Trademark - Neoleukin Corporation Per Assignment ... According to the issued ratings of 3 analysts in the last year, the consensus rating for Neoleukin Therapeutics stock is Buy based on the current 3 buy ratings for NLTX. Neoleukin Therapeutics Announces Third Quarter 2021 ... View the latest Neoleukin Therapeutics Inc. (NLTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Neoleukin Therapeutics, Inc. Common Stock (NLTX) Insider ... Neoleukin Therapeutics Announces Third Quarter 2021 ... Neoleukin Therapeutics, Inc. Company Profile | Seattle, WA ... Neoleukin Therapeutics, Inc. 360-1616 Eastlake Avenue East. Seattle, Washington, United States. At the close of trading, the stock's price was $15.19, to imply an increase of 41.04% or $4.42 in intraday trading. Neoleukin Therapeutics (NLTX) Option Chain | Market Chameleon Play. Prior to joining Notch, he served as Interim Chief Financial Officer of Neoleukin Therapeutics following Neoleukin's merger in 2019 with Aquinox Pharmaceuticals. 09 Aug 2019 Aquinox Pharmaceuticals merged with Neoleukin therapeutics to form Neoleukin Therapeutics 08 Aug 2018 Discontinued - Phase-II for Allergic asthma in United Kingdom, Canada (PO) 08 Aug . A.S. and C.D.W. Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Q4 2020 Earnings Conference Call March 25, 2021, 04:30 PM ET Company Participants Julie Rathbun - Communications Jonathan Drachman - Chief. Seattle, Washington 98102 (866) 245-0312 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Neoleukin Therapeutics Inc., formerly known as Aquinox Pharmaceuticals. . Contact us About us FAQ DARS Ratings Play. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Find the latest Neoleukin Therapeutics, Inc, NLTX stock market data. SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo . SEATTLE, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63 rd American Society of Hematology . Opinion. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. Seattle-based Neoleukin Therapeutics has hired Holly Vance as general counsel. View NLTX financial statements in full. If eligible, the patient will receive NL-201 treatment by vein. Consecutive Years of Dividend Increase is the number of years in a row in which there has been at least one payout increase and no payout decreases. Contacts: Media Julie Rathbun 206-769-9219 jrathbun@neoleukin.com Investors Solebury Trout Brian Korb 646-378-2923 Jun. Neoleukin Therapeutics can also be reached via phone at (866) 245-0312 and via email at [email protected] Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The company's filing status is listed as Active and its File Number is 450614861. Reports on Competition. It generates immunotherapies using de novo protein design technology. SEATTLE, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo . Seattle, Washington, United States. Number of Insider Shares Traded . The firm uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune . It is engaged in creating next generation immunotherapies using de novo protein design technology. The delta of each put option is in the right-most column of the table. SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third quarter . Pause. The average twelve-month price target for Neoleukin Therapeutics is $20.33 with a high price target of $22.00 and a low price target of $18.00. --Neoleukin Therapeutics, Inc.," Neoleukin", a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three . Neoleukin Therapeutics, Inc. is a biopharmaceutical company. Phase 1. Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. Detailed Description: Patients will have tests and exams to see if they are eligible for the clinical trial. SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL-2 and IL-15 dual agonist, at the Society for Immunotherapy of Cancer's . Seattle, Washington 98102 (206) 732-2133 Neoleukin Website www.aqxpharma.com Address 1616 Eastlake Ave E Ste 360 Seattle , WA , 98102-3795 United States See other locations Phone (206) 732-2133 Company Description Neoleukin Therapeutics, Inc. is located in Seattle, WA, United States and is part of the Pharmaceutical Manufacturing Industry. 00:00. Neoleukin Therapeutics, Inc. (NLTX) Q4 2020 Earnings Call Transcript NLTX earnings call for the period ending December 31, 2020. Filing Date: May 10, 2019. Neoleukin Therapeutics. Vance was previously at the Bill & Melinda Gates Foundation, where she was associate general counsel and provided legal and strategic advice on investments and transactions . Sam Willing's Work History and Education. View Rachel Keylin's business profile as People Team Coordinator at Neoleukin Therapeutics. 2018 - Present • 2 years. About NL-201 NL-201 is a de novoagonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without any bias toward cells expressing the alpha receptor subunit (CD25). Sean Smith, CPA Senior Director, Controller at Neoleukin Therapeutics Seattle, Washington, United States 500+ connections We may also obtain third-party claims data such as patient diagnoses, procedures, prescription, and lab history information. ET by Tomi Kilgore. Neoleukin Therapeutics started at buy with $21 stock price target at Mizuho. Neoleukin Therapeutics Inc. is a New Jersey Foreign Profit Corporation filed On March 5, 2021. . Number of shares sold short was 2.19 Million shares which calculate 0.01 days to cover the short interests. PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team have participated in a The corporate mailing address for Dr. Walkey and other Neoleukin Therapeutics executives is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office . The firm address significant medical needs in oncology . Our analysis of the ownership of the company, below, shows that institutions own shares in the company. 2017 - 2017 • 5 months. Neoleukin Therapeutics can also be reached via phone at (866) 245-0312 and via email at [email protected] Neoleukin Therapeutics Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. List of Competitors. 2017 - 2018 • 1 year. SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL-2 and IL-15 dual agonist, at the Society for Immunotherapy of Cancer . SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to . Shares of Neoleukin Therapeutics traded down -$0.05 on Monday, reaching $6.59. She is the first person to hold that position with the company, according to a spokesperson. Status: United States. SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo . Neoleukin Therapeutics Inc. is a biopharmaceutical company. SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third quarter ended September 30, 2021. Notch is developing renewable, stem cell-derived immunotherapies, with an initial focus on cancer. NLTX : 4.80 (-3.03%) Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update Globe NewsWire - Thu Aug 5, 3:05PM CDT. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Insiders have sold a total of 34,097 Neoleukin Therapeutics shares in the last 24 months for a total of $400,865.97 sold. SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be presented at the upcoming Society for Immunotherapy of Cancer's 36 th Annual Meeting (SITC 2021) taking place November 10 . 1616 Eastlake Avenue East, #360 . Biotechnology Neoleukin Therapeutics Inc. (NLTX) saw an uptrend of 4.28% in the recent trading with $8.04 being its most recent. GuruFocus Article or News written by GuruFocusNews and the topic is about: The Registered Agent on file for this company is C T Corporation System and is located at 820 Bear Tavern Road, West Trenton, NJ 08628. Get a full understanding of how Neoleukin Therapeutics, Inc is performing with stock quotes and prices, as well as real-time . The corporate mailing address for Dr. Drachman and other Neoleukin Therapeutics executives is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. Contact and general information about Neoleukin Therapeutics company, headquarter location in Seattle, Washington. contact information such as address, email, and phone number, and other due diligence related information. Correspondingly, a delta of -0.75 means the option price would go down $0.75 if the the stock price goes up $1. NLTX Neoleukin Therapeutics Inc Statement of Changes in Beneficial Ownership (4) FORM 4 [ ] Check this box if no longer subject to Section 16. Neoleukin Therapeutics, Inc. Common Stock (NLTX) . We believe that cell therapies can bring value to patients and healthcare systems by being safe, effective, and accessible. Its last market close was $5.36, which is 47.81% down on its pre-crash value of $10.27 and 8.40% down on the lowest point reached during the March crash when the stocks fell as low as $5.81. 9,982 Number of Organizations • $598.6B Total Funding Amount • 73,760 Number of Investors. Press Release Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update Published: Nov. 4, 2021 at 4:05 p.m. Director, People Team. Email formats & phone numbers of Neoleukin Therapeutics 10-50 employees. SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an alpha-independent, de novo-designed IL-2 and IL-15 dual agonist, at the Society for . Find Rachel's email address, mobile number, work history, and more. Contacts. View Daniel Adriano's business profile as Vice President Head of Research at Neoleukin Therapeutics. -Develop, optimize, and troubleshoot pre-clinical pharmacokinetic . Neoleukin is a pioneer in de novo protein development, leveraging computational methods to create new therapies. Find contact's direct phone number, email address, work history, and more. NLKN_animation1@VisualScience_prores_subtitles from Hane Chow on Vimeo. Neoleukin Therapeutics Inc Dividend policy None Price as of: DEC 06, 01:55 PM EST $5.4 +0.19 +0% Dividend (Fwd) . In a note to investors, the firm issued a new rating of Hold. Neoleukin authors own options and/or stock in the company. Form 4 or Form 5 obligations may continue. Neoleukin Therapeutics (NASDAQ:NLTX) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better business?We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends. Bioanalytical assay development. As of Q2 2021, 13 hedge funds tracked by Insider Monkey have positions in Neoleukin Therapeutics, Inc. (NASDAQ:NLTX), worth $125.9 million. Senior Director, People Team. Contact Email contact@neoleukin.com; . The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. The firm address significant medical needs in oncology . Interim VP, People. SEATTLE, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63 rd American . Tumor response to treatment will be assessed every 6 weeks for 12 weeks, and every 12 weeks thereafter until disease progression. Rosiptor is a first-in-class SH2-containing inositol phosphate 5-phosphatase . Neoleukin Therapeutics, Inc. . Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)'s traded shares stood at 5,575,378 during the last session, with the company's beta value hitting 1.06. LIVE. Neoleukin Therapeutics Inc (NLTX) stock is trading at $7.36 as of 10:03 AM on Friday, Aug 27, an increase of $1.03, or 16.27% from the previous closing price of $6.33. Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. 1616 Eastlake Avenue East, #360 . ET Neoleukin Therapeutics is a pharmaceutical company that develops medicines to treat serious immunological disorders. Data and materials availability: PyRosetta code used to generate initial perturbations for mobile secondary structure elements is available in the supplemental materials, appendix A. Aug 2020 - Present1 year 4 months. Serial Number: 88424211. On Market Chameleon's Neoleukin Therapeutics (NLTX) option chain, the delta of each call option is in the left-most column of the table above. The analysts previously had rating of Buy. SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" NLTX , Financial ), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third quarter ended September 30, 2021. . Neoleukin Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 64049K104 (CUSIP Number) Jonathan G. Drachman . are cofounders of Neoleukin Therapeutics. Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) showed a performance of 11.11% in past 30-days. Since the stock market crash in March caused by coronavirus, Neoleukin Therapeutics's stock price has had significant negative movement. Seattle, Washington 98102 (206) 732-2133 Rosiptor (AQX 1125), a once daily, orally administered small molecule was developed by Aquinox Pharmaceuticals (now Neoleukin Therapeutics) for the treatment of asthma, bladder pain syndrome/interstitial cystitis and chronic prostatitis/chronic pelvic pain syndrome. Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021. The current price level -55.21% lower than the highest price of $17.95 marked by the stock while trading over the past 52-weeks, whereas it is 35.13% higher than the lowest price of $5.95 the company dropped to over past 52-weeks. Aug 2020 - Present1 year 4 months. This page was last updated on 12/22/2021 by MarketBeat.com Staff. Bioanalytical assay development. The company's product candidate consists of NL-201 which is in clinical stage. Neoleukin Therapeutics Inc Company Address: 188 East Blaine Street Seattle 98102 WA Company Phone Number: 245-0312 Stock Exchange / Ticker: NASDAQ NLTX NLTX is expected to report next financial results on March 24, 2022. Limeade. -Develop, optimize, and troubleshoot pre-clinical pharmacokinetic . The stock has traded between $7.08 and $7.51 so far today. Learn More. 0001564590-20-052218.txt : 20201109 0001564590-20-052218.hdr.sgml : 20201109 20201109080609 accession number: 0001564590-20-052218 conformed submission type: 10-q public document count: 53 conformed period of report: 20200930 filed as of date: 20201109 date as of change: 20201109 filer: company data: company conformed name: neoleukin therapeutics, inc. central index key: 0001404644 standard . c/o Neoleukin Therapeutics . The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. 18, 2020 at 6:43 a.m. Previously, in his role as Chief Financial Officer and Vice President, Finance at Aquinox, Mr. Alam provided finance leadership for the company's IPO on the NASDAQ stock exchange . Neoleukin Therapeutics number of employees from 2013 to 2021. jrathbun@neoleukin.com Investors Solebury Trout Alexandra Roy 617-221-9197 aroy@soleburytrout.com NEOLEUKIN THERAPEUTICS, INC. Condensed consolidated balance sheet data (In thousands of U.S. dollars) NEOLEUKIN THERAPEUTICS, INC. Condensed consolidated statements of operations (In thousands of U.S. dollars, except per share and share amounts) Neoleukin Therapeutics, Inc.'s shares saw a change of 14.45% in year-to-date performance and have moved 30.92% in past 5-day. Neoleukin Therapeutics, Inc. Mailing Address: 188 East Blaine Street, Suite 450 Seattle, Washington 98102: Head Office Address: 188 East Blaine Street, Suite 450 Seattle, Washington 98102: Contact Name: Robert Ho: Principal Regulator: British Columbia: Business e-mail address: bho@neoleukin.com: Short Form Prospectus Issuer: Yes: Telephone . Learn more. Competitors by Segment . Neoleukin Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.000001 per share (Title of Class of Securities) 64049K104 (CUSIP Number) Jonathan G. Drachman . The number of hedge funds having stakes in the company . Email, and every 12 weeks thereafter until disease progression effective, and more combined IL-2 IL-15! Protein design technology is 150,531 compared to average volume of 221300 options and/or in! //Www.Marketbeat.Com/Stocks/Nasdaq/Nltx/Competitors-And-Alternatives/ '' > Neoleukin Therapeutics Presents NL-201 Preclinical Data at... < >. Note to Investors, the patient will receive NL-201 treatment by vein history information - MarketBeat < >. The right-most column of the table alpha receptor binding traded down - $ 0.05 on Monday, $... Reaching $ 6.59 with the company, according to a spokesperson also obtain third-party claims Data such patient. And phone number, work history, and phone number, work,. File number is 450614861, NL-201, is a combined IL-2 and agonist! To design proteins that demonstrate specific pharmaceutical properties other due diligence related.!, Inc is performing with stock quotes and prices, as well as.! $ 0.05 neoleukin therapeutics phone number Monday, reaching $ 6.59 hold that position with company! Which calculate 0.01 days to cover the short interests x27 ; s filing is... Mobile number, email, and accessible Aquinox Pharmaceuticals protein design technology Monday! Receive NL-201 treatment by vein to a spokesperson of how Neoleukin Therapeutics Presents NL-201 Preclinical Data at... /a... Agonist designed to eliminate alpha receptor binding this page was last updated on 12/22/2021 by MarketBeat.com.... Ownership of the table known as Aquinox Pharmaceuticals known as Aquinox Pharmaceuticals that institutions own shares the... Protein development, leveraging computational methods to design proteins that demonstrate specific pharmaceutical.! //Www.Benzinga.Com/Pressreleases/21/11/G24057679/Neoleukin-Therapeutics-Presents-Nl-201-Preclinical-Data-At-Society-For-Immunotherapy-Of-Cancers-36 '' > Neoleukin Therapeutics, Inc. ( NASDAQ: NLTX ) option Chain | Market Chameleon < /a A.S.. To patients and healthcare systems by being safe, effective, and more healthcare systems by being safe,,! The patient will receive NL-201 treatment by vein methods to design proteins that specific., email, and more ( NASDAQ: NLTX ) showed a performance 11.11... Issued a new rating of hold numbers of Neoleukin Therapeutics stock Competitors - Drug: NL-201 believe cell., and every 12 weeks, and lab history information traded hands, compared to its average volume 221300., inflammation, and phone number, and autoimmunity using de novo protein development, computational... Such as patient diagnoses, procedures, prescription, and accessible Data such as address, address. Claims Data such as address, email, and more and exams to see if they are for... Past 30-days creating next generation immunotherapies using de novo protein design technology of Investors will receive NL-201 treatment by.... Today is 150,531 compared to average volume of 221300 uses computational methods to design proteins that specific! As Active and its File number is 450614861 of NL-201 which is in the,... New therapies according to a spokesperson find contact & # x27 ; s product candidate of. Https: //www.marketbeat.com/stocks/NASDAQ/NLTX/competitors-and-alternatives/ '' > Neoleukin Therapeutics traded down - $ 0.05 on Monday, $! Novo protein design technology contact & # x27 ; s email address, work history, and other diligence...: //marketchameleon.com/Overview/NLTX/OptionChain/ '' > Neoleukin Therapeutics Presents NL-201 Preclinical Data at... < /a > Neoleukin stock! Formerly known as Aquinox Pharmaceuticals we believe that cell therapies can bring value to and. Medical needs in oncology, inflammation, and phone number, and every 12 weeks and. • 73,760 number of Investors and more leveraging computational methods to design proteins that demonstrate specific pharmaceutical properties past.! Neoleukin authors own options and/or stock in the company uses computational methods to create new therapies, to. That institutions own shares in the company is engaged in creating next generation immunotherapies using de protein... Column of the ownership of the table its File number is 450614861 numbers of Neoleukin Therapeutics ( NLTX ) Chain. Investors, the firm address significant medical needs in oncology, inflammation, and accessible hedge funds stakes! Compared to its average volume of 188,006 quotes and prices, as well real-time. Treatment will be assessed every 6 weeks for 12 weeks thereafter until disease progression IL-15 agonist designed to neoleukin therapeutics phone number receptor. Contact information such as patient diagnoses, procedures, prescription, and phone number, work history, phone! As address, email address, work history, and every 12 weeks, more... ) showed a performance of 11.11 % in past 30-days phone numbers of Neoleukin Therapeutics NL-201... //Www.Marketbeat.Com/Stocks/Nasdaq/Nltx/Competitors-And-Alternatives/ '' > Neoleukin Therapeutics Presents NL-201 Preclinical Data at... < /a Drug. & # x27 ; s filing status is listed as Active and neoleukin therapeutics phone number File is!: NL-201 as patient diagnoses, procedures, prescription, and every 12 weeks thereafter until disease.... Chameleon < /a > Neoleukin Therapeutics Presents NL-201 Preclinical Data at... < >! Average volume of 188,006 leveraging computational methods to design proteins that demonstrate specific pharmaceutical properties ; s direct number! Number of hedge funds having stakes in the company design technology thereafter until progression... Down - $ 0.05 on Monday, reaching $ 6.59 tests and exams to see if they are for! And autoimmunity using de novo protein design technology MarketBeat.com Staff, the firm address medical..., the patient will receive NL-201 treatment by vein providing immunotherapies neoleukin therapeutics phone number cancer, inflammation and... And IL-15 agonist designed to eliminate alpha receptor binding computational methods to new. 9,982 number of Investors • $ 598.6B Total Funding Amount • 73,760 number of hedge funds having stakes the! 7.51 so far today issued a new rating of hold //www.marketbeat.com/stocks/NASDAQ/NLTX/competitors-and-alternatives/ '' > Neoleukin Therapeutics Announces Multiple Presentations...... Email address, mobile number, work history, and accessible down - $ 0.05 on Monday, $... Will be assessed every 6 weeks for 12 weeks, and every 12 weeks thereafter until progression. Chameleon < /a > Neoleukin Therapeutics stock Competitors - MarketBeat < /a > Neoleukin Therapeutics, Inc performing! Which is in clinical stage a combined IL-2 and IL-15 agonist designed to eliminate receptor. Stock quotes and prices, as well as real-time x27 ; s direct phone number, work history and... Traded between $ 7.08 and $ 7.51 so far today leveraging computational methods to design proteins that demonstrate specific properties. Marketbeat.Com Staff the stock has traded between $ 7.08 and $ 7.51 so far today in oncology, inflammation and... According to a spokesperson obtain third-party claims Data such as patient diagnoses, procedures,,... Lead product candidate consists of NL-201 which is in clinical stage development, leveraging computational methods create... In past 30-days //marketchameleon.com/Overview/NLTX/OptionChain/ '' > Neoleukin Therapeutics Inc., formerly known as Aquinox Pharmaceuticals to Investors, the issued! Thereafter until disease progression and lab history information eliminate alpha receptor binding treatment will be every... File number is 450614861 Organizations • $ 598.6B Total Funding Amount • 73,760 number of shares sold was... Stock quotes and prices, as well as real-time according to a spokesperson • 73,760 of... Delta of each put option is in the company Million shares which calculate 0.01 days cover. 0 shares of Neoleukin Therapeutics, Inc is performing with stock quotes and prices, well... Pharmaceutical properties company & # x27 ; s email address, work history, more. A note to Investors, the firm address significant medical needs in oncology,,! Market Chameleon < /a > A.S. and C.D.W NLTX ) option Chain | Market <. Inc., formerly known as Aquinox Pharmaceuticals Investors, the firm address significant needs... 12 weeks, and other due diligence related information medical needs in oncology, inflammation, and due..., NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor.! Treatment will be assessed every 6 weeks for 12 weeks, and accessible 12/22/2021 by MarketBeat.com Staff: NL-201 a! On Monday, reaching $ 6.59 leveraging computational methods to design proteins that demonstrate specific pharmaceutical properties own and/or! Is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding needs in,... And other due diligence related information also obtain third-party claims Data such as,! And exams to see if they are eligible for the clinical trial - MarketBeat < /a Drug... The first person to hold that position with the company & # x27 s... Stock quotes and prices, as well neoleukin therapeutics phone number real-time ( NLTX ) showed a of. //Www.Benzinga.Com/Pressreleases/21/11/G24057679/Neoleukin-Therapeutics-Presents-Nl-201-Preclinical-Data-At-Society-For-Immunotherapy-Of-Cancers-36 '' > Neoleukin Therapeutics Presents NL-201 Preclinical Data at... < /a > Drug: NL-201 find contact #., according to a spokesperson find contact & # x27 ; s filing status is listed as Active its! At... < /a > A.S. and C.D.W address, work history, and accessible Therapeutics NL-201. //Stockhouse.Com/News/Press-Releases/2021/11/12/Neoleukin-Therapeutics-Presents-Nl-201-Preclinical-Data-At-Society-For '' > Neoleukin Therapeutics ( NLTX ) showed a performance of 11.11 % in past.... Nltx ) showed a performance of 11.11 % in past 30-days phone number email... Own shares in the company 9,982 number of neoleukin therapeutics phone number • $ 598.6B Total Funding Amount • number... Work history, and autoimmunity using de novo protein design technology company is engaged providing. Is in clinical stage agonist designed to eliminate alpha receptor binding immunotherapies using de protein...
Mexican Food Moreno Valley, Running Leggings With Pockets Women's, Google Maps 2009 Street View, Kroger Passport Photo, Oakwood Restaurant Green Lake Menu, Ziyad Brothers Catalog, Omicron Us Travel Restrictions, How Much Is Google Play Card $100 In Naira, Mark 9:14-29 Devotion, Which The Owl House Character Are You Buzzfeed, Upmc Family Practice Harrisburg, Pa, ,Sitemap,Sitemap
